Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- European shares subdued as surging crude sharpens focus on ECB rate path
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cempra, Inc. (CEMP) PT Lowered to $4 at Stifel; Reiterates Hold
March 1, 2017 8:59 AM ESTStifel lowered its price target on Cempra, Inc. (NASDAQ: CEMP) to $4.00 (from $8.00) while maintaining a Hold rating. GAAP net loss of $31.5M, or $(0.60)/share, was wider than Consensus' $(0.55) estimates.
Analyst Stephen Willey commented, "Incremental solithromycin updates provided on managements 4Q16 earnings announcement/call... More
Cempra (CEMP) Underperform Rating Reiterated at Baird Post Q4
February 28, 2017 12:45 PM ESTJefferies analyst Brian Skorney reiterated his Underperform rating and $2 price target on Cempra, Inc. (NASDAQ: CEMP) following results.
Skorney commented, "Cempra reported in-line earnings in 4Q16, along with a host of trial discontinuations, failure in gonorrhea, and updates on discussions with... More
Cempra (CEMP) Misses Q4 EPS by 1c, to Reduce Workforce
February 28, 2017 6:52 AM ESTCempra (NASDAQ: CEMP) reported Q4 EPS of ($0.60), $0.01 worse than the analyst estimate of ($0.59).
Corporate Restructuring Action
As a consequence of the CRL we received, and subsequent discussions with the FDA, resulting in a delay of the potential approval of solithromycin, we recently... More
